Document is current
Any future updates will be listed below
-
Authors
Chockley, Peter J. https://orcid.org/0000-0002-5181-2696
Ibanez-Vega, Jorge https://orcid.org/0000-0003-4317-8573
Krenciute, Giedre https://orcid.org/0000-0003-4335-0644
Talbot, Lindsay J.
Gottschalk, Stephen https://orcid.org/0000-0003-3991-7468
-
Funding
Funding for this research was provided by:
Center for Strategic Scientific Initiatives, National Cancer Institute (P30 CA021765, R50 CA211481, P30 CA021765, P30 CA021765)
St Jude Sumara Fellowship
The Garwood Postdoctoral Fellowship
ChadTough Foundation
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (R01NS121249)
Rally Foundation
American Lebanese Syrian Associated Charities
- License Information
-
More Information
Article History
Received: 27 January 2022
Accepted: 16 December 2022
First Online: 2 February 2023
Competing interests
: S.G. and P.J.C. have patent applications in the fields of NK and T cell and/or gene therapy for cancer. S.G. has a research collaboration with TESSA Therapeutics, is a Data and Safety Monitoring Board member of Immatics and was on the scientific advisory board of Tidal. P.J.C. is a technical consultant for LUMICKS.
